First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
Completed · Phase 1 · NCT04417465
Conditions: Advanced Solid Tumors Cancer
At a glance
- Research payments reported, 2025
- $37,542
- U.S. investigators named
- 5
- Sites paid
- 9
- Planned or actual enrollment
- 101
About the trial
- Sponsor
- AbbVie (with Calico Life Sciences LLC)
- Tested
- ABBV-CLS-579 (drug), PD-1 inhibitor (drug), VEGFR TKI (drug)
- Dates
- Started 2020-06-03; completion 2025-08-21
- Results posted
- Not yet
The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone and in combination with a PD-1 target agent or with a VEGF TKI. ABBV-CLS-579 is an investigational drug being developed for the treatment of tumors. The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-579 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation, and Part 3 Combination Dose Expansion. Part 1, ABBV-CLS-579 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors. Part 2, ABBV-CLS-579 will be administered at escalating …
From ClinicalTrials.gov, last updated 2025-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $37,542 in research payments for this study in 2025 (12 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Sunil Babu, M.D. Medical Oncology · Fort Wayne, IN
- Patricia M. Lorusso, DO Medical Oncology · Detroit, MI
- John D. Powderly II, M.D. Hematology & Oncology · Huntersville, NC
- Jason Luke, M.D. Hematology & Oncology · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Pittsburgh Cancer Institute $25,472
- Fort Wayne Medical Oncology and Hematology American Oncology PArtners $4,200
- Yale School of Medicine $2,100
- Carolina Biooncology Institute PLLC $1,500
- Yale University $1,200
- UPMC Hillman Cancer Center $1,050
- Highlands Oncology Group $875
- Carolina Biooncology Institute $875
- Fort Wayne Medical Oncology & Hemat $270
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.